International Journal of Clinical Case Reports 2024, Vol.14, No.5, 276-289 http://medscipublisher.com/index.php/ijccr 278 comprehensive diagnostic approach that includes clinical evaluation, neuroimaging, and genetic testing. Such an integrated approach not only aids in early diagnosis but also provides critical information for planning appropriate interventions and supports for patients and their families, potentially improving the quality of life and delaying the progression of the disease. 3 Diagnostic Tools and Biomarkers for Early Detection 3.1 Neuroimaging techniques: MRI and PET scans Neuroimaging techniques, particularly Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) scans, have become pivotal in the early detection of Alzheimer’s Disease (AD). MRI is commonly used to assess structural brain changes, such as hippocampal atrophy, which is one of the earliest signs of AD. Recent advances have allowed for the quantification of these changes, improving the sensitivity of MRI in distinguishing between normal aging and AD-related degeneration. PET scans, on the other hand, provide functional insights by detecting metabolic changes and the accumulation of pathologic biomarkers like amyloid-beta plaques and tau protein aggregates. The combination of PET with specific tracers, such as [18F]-fluorodeoxyglucose (FDG), allows for the assessment of glucose metabolism in the brain, which is typically reduced in AD-affected regions. Amyloid and tau PET imaging are increasingly used to visualize the distribution of these proteins in vivo, offering a clearer understanding of the disease's progression and aiding in early diagnosis (Bao et al., 2017). Furthermore, the integration of multimodal imaging, such as PET/MRI, enhances diagnostic accuracy by combining structural and functional information. This hybrid approach is particularly useful for early detection, as it can simultaneously capture amyloid deposition, brain atrophy, and metabolic dysfunction, providing a comprehensive view of the pathological changes associated with AD. 3.2 Cerebrospinal fluid (CSF) and blood biomarkers Cerebrospinal fluid (CSF) biomarkers have long been used to aid in the early diagnosis of Alzheimer’s Disease (AD). Key biomarkers include amyloid-beta (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau), which reflect the core pathologies of amyloid plaque formation and neurofibrillary tangle accumulation, respectively. Studies have shown that the ratios of Aβ42 to t-tau and p-tau are particularly effective in distinguishing between AD and other forms of dementia, as well as in predicting progression from mild cognitive impairment (MCI) to AD (Palmqvist et al., 2015). In recent years, there has been significant progress in the development of blood-based biomarkers as a less invasive alternative to CSF analysis. Plasma levels of amyloid-beta and tau, as well as neurofilament light chain (NfL), have shown promise in reflecting AD pathology and correlating with changes seen in CSF and PET imaging. These blood biomarkers are advantageous for large-scale screening and monitoring of disease progression due to their accessibility and cost-effectiveness compared to CSF sampling or advanced imaging techniques. Despite the potential, challenges remain in achieving the sensitivity and specificity required for reliable early diagnosis, and further research is needed to standardize the use of these biomarkers in clinical practice. The combination of blood biomarkers with traditional CSF analysis and neuroimaging holds the potential to improve early diagnosis and tracking of disease progression in a clinical setting. 3.3 Case study analysis: utilizing diagnostic tools for early detection A case study involving a 65-year-old male presenting with mild cognitive impairment (MCI) highlights the utility of combining advanced neuroimaging and biomarker analysis for early diagnosis of Alzheimer’s Disease (AD). Initial assessments revealed subtle memory deficits and executive dysfunction. MRI showed significant hippocampal atrophy, while PET imaging with [18F]-fluorodeoxyglucose (FDG) demonstrated reduced metabolic activity in the posterior cingulate cortex, a region typically affected in early AD. Amyloid PET confirmed extensive amyloid deposition. Concurrently, CSF analysis indicated reduced Aβ42 levels and elevated t-tau and p-tau, consistent with AD pathology. Despite the patient’s relatively mild symptoms, the combination of imaging and CSF biomarkers provided strong evidence for an early diagnosis of AD, prompting the initiation of therapeutic interventions aimed at slowing disease progression (Wang et al., 2023).
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==